Clinical trial: Combining durvalumab with novel agents increases pathological responses in ...
The NeoCOAST-2 study showed durvalumab combined with Dato-DXd achieved the highest pathological complete response rates among tested regimens for resectable NSCLC, with Arm 4 yielding a 34.1% pCR rate and a favorable safety profile.
Related Clinical Trials
Highlighted Terms
Related News
NeoCOAST-2 trial showed high pathologic complete response (pCR) and major pathologic response (mPR) rates in resectable NSCLC patients treated with novel combinations, with Dato-DXd plus durvalumab and single-agent platinum chemotherapy achieving the highest pCR (34.1%) and mPR (65.9%) rates. All arms demonstrated manageable safety profiles and comparable surgical rates.
The NeoCOAST-2 study showed durvalumab combined with Dato-DXd achieved the highest pathological complete response rates among tested regimens for resectable NSCLC, with Arm 4 yielding a 34.1% pCR rate and a favorable safety profile.
Durvalumab combined with datopotamab deruxtecan showed highest pathologic complete response rates in NeoCOAST-2 trial for resectable NSCLC, with 34.1% in arm 4, and a favorable safety profile.
Adding novel agents to perioperative durvalumab for NSCLC led to higher pCR and mPR rates compared to historical rates with durvalumab and chemotherapy. The highest response rates occurred with the addition of Dato-DXd (pCR 34.1%, mPR 65.9%). All combinations demonstrated manageable safety profiles and surgical rates comparable to approved regimens.